KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Invested Capital (2016 - 2026)

Gilead Sciences filings provide 17 years of Invested Capital readings, the most recent being $47.6 billion for Q4 2025.

  • On a quarterly basis, Invested Capital rose 3.29% to $47.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $47.6 billion, a 3.29% increase, with the full-year FY2025 number at $47.6 billion, up 3.29% from a year prior.
  • Invested Capital hit $47.6 billion in Q4 2025 for Gilead Sciences, up from $46.4 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $49.9 billion in Q2 2021 to a low of $41.5 billion in Q2 2024.
  • Median Invested Capital over the past 5 years was $46.4 billion (2023), compared with a mean of $46.2 billion.
  • Biggest five-year swings in Invested Capital: skyrocketed 162.63% in 2021 and later dropped 11.83% in 2024.
  • Gilead Sciences' Invested Capital stood at $47.8 billion in 2021, then decreased by 2.77% to $46.4 billion in 2022, then increased by 2.8% to $47.7 billion in 2023, then fell by 3.55% to $46.0 billion in 2024, then increased by 3.29% to $47.6 billion in 2025.
  • The last three reported values for Invested Capital were $47.6 billion (Q4 2025), $46.4 billion (Q3 2025), and $44.5 billion (Q2 2025) per Business Quant data.